Introduction
Changing demographics, increasing affluence and sedentary lifestyles have led to the increasing prevalence of non-communicable lifestyle diseases like diabetes mellitus (DM), obesity, hypertension (HTN), cardiovascular disease (CVD) and chronic kidney disease (CKD), even in developing countries like India. It is estimated that 80% of chronic disease deaths now occur in low-and middle-income countries [1] . CKD is important among this group as, apart from its own morbidity, mortality and high risk for progression to end-stage renal disease (ESRD), it has also been found to be an important independent risk factor for CVD [2, 3] . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7) guidelines recommend that glomerular filtration rate (GFR) <60 mL/min/ 1.73 m 2 or the presence of microalbuminuria (MAU) be considered cardiovascular disease equivalents [4] . Data from the US population studies like the Third National Health and Nutrition Examination Survey (NHANES III) and the Kidney Early Evaluation Program (KEEP) show that 11-15.6% of adult US population has chronic kidney disease [5, 6] . Comparison of the NHANES 1994-98 and 1999-2004 data shows an increase in prevalence from 10.03% to 13.07% [7] . In the absence of a proper registry and paucity of population-based studies, exact prevalence of CKD in India is not known. Based on data from major tertiary care centres, the presumptive estimates of incidence of ESRD in India are 100 per million population (p.m.p.) [8] . Till recently, there were only three population-based studies on the prevalence of CKD in India. Modi et al. studied end-stage renal disease (ESRD) in a captive draining population of a tertiary care centre [9] . Mani et al. used an initial screening with questionnaire and dipstick urine analysis [10] , and Agarwal et al. used serum creatinine value >1.8 mg/dL as cutoff for defining CKD [11] . These studies estimated prevalence of overt CKD or ESRD in India as 0.79-1.39%. A recent community-based study found 4.2% with low estimated GFR (eGFR) in a North Indian population. Even this study estimates only stages III-Vof CKD suggesting that actual prevalence may be much higher than previously estimated [12] . The aim of the present study was to screen a population of apparently healthy central government employees (CGEs) from India for early stages of CKD.
Materials and methods

Study design
This cross-sectional study was carried out in Agra city in North India from March 2008 to July 2009. CGEs and their families were invited to participate in a 'Comprehensive Health Survey Camp for Detection of Life Style Diseases' after a series of health lectures on lifestyles diseases like obesity, DM, HTN, CVD and CKD. These camps were organized at the local hospital or close to the workplace of the employees. CGEs have transferable jobs and are comprised of a mix of people from all regions and ethnicities of India. Our sample is comprised of individuals from 23 states and one union territory (UT). The study protocol was approved by the Ethics Committee of Military Hospital Agra.
The study population included all healthy adults above 18 years of age. The participants were asked to report after an overnight fast to the survey location where, after obtaining informed consent, they were administered a pre-structured, standardized questionnaire covering demographic data, risk factors, detailed personal, family and medical history, and lifestyle habits. Anthropometric parameters were assessed using standardized techniques. Body weight and height were measured in light clothes without footwear on a dedicated calibrated weighing scale and stand-alone stadiometre. For waist and hip circumference, a standardized clinician's tape measure was used to measure the widest part of the hips and then the narrowest part of the waist at or above the umbilicus. Every participant underwent a sitting right arm blood pressure measurement after 10-15 min rest by two separate nurses at an interval of at least 10 min using two dedicated calibrated mercury sphygmomanometres, and the mean of two measurements was used for all analysis. A spot, early morning urine sample was obtained. Assessment for proteinuria, haematuria and leucocyturia was done using dipsticks (M10SG Multisticks ® , Seimens ® Corp, India), and the results were read on Clinitek ® 50 semi-automated urine analyser (Seimens Corp, India). A reading of 'small' or greater for blood and leucocytes, corresponding to >0.03 mg/dL of blood and >5-15 leucocytes per high-power field (hpf) in urine, respectively, was considered positive for haematuria and leucocyturia. Semi-quantitative urinary microalbumin and albumin:creatinine ratio (ACR) was obtained using Clinitek ® Microalbumin strips read on Clinitek ® 50 semi-automated urine analyser (Seimens ® Corp, India). Semi-quantitative results for urinary microalbumin were obtained in four classes: 10, 30, 80 or 150 mg/L and urinary creatinine in five categories: 10, 50, 100, 200 or 300 mg/dL. ACR was calculated by the analyser from the actual reflectance values of albumin and creatinine reaction pads and given in three categories: <30, 30-300, >300 mg/g. ACR value of 30-300 mg/g was considered as MAU, while values <30 mg/g and >300 mg/g were considered as normal and macroalbuminuria, respectively.
A 5-mL sample of fasting venous blood was taken for assessing biochemical variables which included creatinine, lipid profile and fasting plasma glucose (FPG). Serum creatinine (Scr), total cholesterol, highdensity lipoprotein (HDL) cholesterol, triglycerides and FPG were measured on Erba Chem 5 biochemistry analyser (Transasia ® Corp, India) using standardized kits from Siemens Diagnostics, India. Scr was estimated by modified Jaffe's kinetic assay (Siemens ® Corp, India). Control samples were included in each run, and daily quality checks were carried out for all analytes. All samples were tested on the day of collection in a single lab for the entire duration of the study.
Inclusion/exclusion and assessment criteria Hypertension Subjects with self-reported HTN or on anti-hypertensive drugs were excluded. In the included study population, HTN was defined as per JNC-7 guidelines [4] . Systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg was considered HTN.
Diabetes mellitus Patients with history of DM or use of anti-diabetic medication were excluded. In the included study population, subjects having FPG >126 were considered to have DM.
Obesity Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. Waist-to-hip ratio (WHR) was calculated as waist circumference divided by hip circumference in centimetres. Overweight and obesity on BMI were defined as >23 and >25, respectively. Truncal obesity by WHR was defined as >0.9 for men and >0.8 for women. These definitions were based on the Association of Physicians of India consensus statement for obesity for an Asian Indian population [13] .
Other exclusions Women during menstrual periods and pregnancy were excluded. The CKD-EPI calculations were based on tables given in the original article [14] . The formula in short is [141 × (Scr / κ)α × 0.993 Age × (1.018 if female)], where κ is 0.7 for females and 0.9 for males, α is −0.329 for females with Scr of <0.7 mg/dL, −0.411 for males with Scr of <0.9 mg/dL, and −1.209 for females and males with Scr ≥0.7 and 0.9 mg/dL, respectively. CKD definitions were based on Kidney Disease Quality Outcomes Initiative (KDOQI) guidelines [15] . MAU, haematuria and/or leucocyturia was taken as an indicator of renal damage (RD) in those with eGFR >60 mL/min/1.73 m 2 . As only healthy individuals were included in the study with an aim to identify early kidney disease, we classified patients from stage 1 to stage 3. 
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Statistical analysis
All data were tabulated on Microsoft Excel worksheets and analysed using statistical software SPSS version 15.0. Chi-square test was used for comparing the prevalence rates between the subgroups and for determining the relationship between various risk factors and CKD at 95% confidence interval (CI). Yates correction was applied where necessary. To compare intergroup differences for the quantitative variables of age and GFR, t-test was used. Multiple logistic regression analysis was carried out to determine the independent association of various risk factors on CKD. A P-value of <0.05 was taken as statistically significant.
Results
A total of 3398 subjects were examined. State/region data were available for 2595 subjects. Of these 2595 subjects, 923 (35.57%) were from the home state of Uttar Pradesh. The remaining 1672 (64.43%) were from other regions of India. Region-wise distribution of subjects is summarized in Table 1 .
Mean age of the population was 35.64 ± 8.72 years with a range of 18-76 years of which 2244 (66.04%) were males and 1154 (33.96%) females. Assessment of obesity using BMI revealed 979 (28.81%) overweight subjects (BMI >23), and 735 (21.63%) were obese (BMI >25). Using WHR, 1941 (57.12%) subjects had truncal obesity (>0.9 for males and >0.8 for females). HTN was found in 447 subjects (13.15%). Only 52 (1.53%) were found to be diabetic (see Supplementary data). Three hundred and eight (9.06%) subjects had hypercholesterolaemia (serum cholesterol >200 mg/dL).
For further analysis of evidence of CKD, 162 subjects were excluded due to pre-existing disease, and 386 patients could not undergo test for MAU due to logistic reasons and were thus not included. A total of 2850 subjects were thereby evaluated for CKD. While evaluating for CKD, 284 subjects (9.96%) had urinary microalbumin >30 mg/ l, and 327 (11.47%) subjects had deranged ACR of 30-300 mg/g. Haematuria and/or leucocyturia was seen in 88 (3.09%) subjects ( On examination of population subgroups of males and females, there were 2244 males and 1154 females with mean age of 35.73 ± 8.44 and 35.44 ± 9.23 years, respectively. The comparative data between the population sub- groups for the various risk factors and stages of CKD are represented in tabular form in Table 3 . Chi-square test was used to determine the differences in the observed characteristics between males and females. There was a highly significant difference observed in the occurrence of overweight individuals, obesity, truncal obesity, HTN and hypercholesterolaemia between the subgroups. No significant difference could be found for FPG. For quantitative variables of mean age and mean GFR, difference between males and females was compared using the t-test, and the difference was found to be not significant for mean age and significant (P < 0.05) for GFR using both MDRD and CKD-EPI equations. While evaluating for CKD, a significant difference was observed for deranged ACR and stage III CKD, whereas no significant difference was observed for MAU, stage 1 CKD and stage 2 CKD. For overall prevalence of CKD, there was a significant difference seen with the MDRD equation but not with CKD-EPI.
To evaluate the independent association of the risk factors of CKD, multiple logistic regression was carried out for the entire population as well as the subgroups. It was observed that, for the total population, age >40 years [odds ratio (OR) = 1.86 (95% CI 1.42-2.43), P < 0.00001] (P < 0.05), FPG >126 mg/dL [OR = 4.18 (95% CI 2.16-8.12), P < 0.00001] and HTN [OR = 1.4 (95% CI 1.01-1.93), P < 0.05] had an independent effect on CKD. In the subpopulation of males, age >40 years [OR = 2.34 (95% CI 1.66-3.3), P < 0.00001], FPG >126 mg/dL [OR = 5.12 (95% CI 2.3-11.4), P < 0.0001] and HTN [OR = 1.49 (95% CI 1.03-2.15), P < 0.05] had an independent effect on CKD. In the subpopulation of females, no independent association could be found for any of the risk factors for CKD.
Discussion
Our study shows that 13.12-15.04% of CGEs have early stages of CKD. This is the first study in India on early stages of CKD based on KDOQI guidelines using MAU as a marker for kidney damage. Previously available studies from tertiary care centres as well as community surveys have looked at the late stages of CKD and/or ESRD and estimated the CKD burden in India as 0.79-1.39% [9] [10] [11] . However, studies in other parts of the world have shown much higher prevalence. The NHANES II and III cohorts show that 10.03% and 13.07% of the US population had CKD in the 1988-94 and 1999-2004, respectively [7] . Tillin et al. found 8.7% MAU in an ethnically South Asian population of Britain who were predominantly first generation migrants of Indian origin [16] , and in Singapore, Nang et al. found 27% CKD in ethnic Indians [17] . A community-based study around Delhi using eGFR by MDRD and Cockroft-Gault (CG) equations found 4.2% of the population had low eGFR (<60 mL/min/1.73 m 2 ) [12] . This corresponds to KDOQI stage 3 and above and is comparable to our data (2.11-3.02% stage III CKD). Our study therefore shows that the burden of CKD, even in a low-risk population of apparently healthy CGEs, is much higher in India than previously estimated. However, since we have carried out only one spot sample for MAU, some of our subjects may have only transient MAU. Further studies with a more inclusive and representative sample including high-risk groups would be required to find the true prevalence of CKD in India.
There are ethnic and racial variations in the prevalence of CKD and MAU. Even within one nation/ethnicity, wide variations by ethnic subgroups in the prevalence of dipstick proteinuria were demonstrated in studies from Pakistan [18] and Southeast Asia [19] . Similar ethnic-/region-wise variations are likely in a large country like India. One of the strengths of our study is the inclusion of subjects from all regions of the country giving a better representation of CKD prevalence than studies from one geographic region or city. However, due to the migratory nature of the study population and small sample size of individual ethnic groups, region-/ethnicity-based conclusions were not possible.
The MDRD study equation was developed by studying people with CKD, and its major limitations are imprecision and systematic underestimation of measured GFR at higher values [20] . The validity of using equations developed on a small cohort of CKD patients for calculating eGFR in healthy subjects in epidemiological studies has been questioned. The CKD-EPI equation was developed to address these shortcomings and claims to have better performance over the MDRD equation especially at higher GFR, with less bias, improved precision and greater accuracy [14] . On comparing the CKD-EPI equation vs the MDRD equation on the NHANES 1999-2006 cohort, the authors report that CKD-EPI equation yields a higher mean eGFR (93.2 ± 0.39 mL/min/1.73 m 2 vs 86.3 ± 0.40 mL/min/1.73 m 2 ) and lower estimated prevalence of CKD (11.5% vs 13.1%). This was mainly due to lower prevalence of stage 3 disease (6.3% vs 7.8%). Reclassification to higher estimated GFR also resulted in a higher prevalence of stage 1 disease and a lower prevalence of stage 2. In our study, although the increase in mean eGFR by CKD-EPI vs MDRD was marginal (100 + 19.48 mL/min/1.73 m 2 vs 98 + 25.25 mL/min/1.73 m 2 ), the overall prevalence showed a similar reduction (13.12% vs 15.04%). Similar comparisons of stage-wise prevalence for CKD-EPI vs MDRD showed that the prevalence increased for stage 1 CKD (6.73% vs 6.62%), and was reduced for stage 2 (4.28% vs 5.40%) and stage 3 CKD (2.11% vs 3.02%). Evaluation on the NHANES cohort also showed that the CKD-EPI equation leads to a lower prevalence in women. In our study, the prevalence for stage 3 CKD in females showed a significant reduction with the CKD-EPI in comparison to MDRD (4.68% vs 7.23%). Performance of the CKD-EPI equation was as expected in our study and may be suitable for use in Indian population. However, studies comparing the measured GFR with the CKD-EPI equation would be required for proper validation. Furthermore, as both MDRD and CKD-EPI use the same variables, such as age, sex and serum creatinine, any systematic bias due to ethnicity is likely to affect both MDRD and CKD-EPI, and ethnicity-and sex-based correction factors may be required.
In India, access to renal replacement therapy (RRT) for CKD and ESRD patients is limited and prohibitively expensive. India has about 700 nephrologists, 400 dialysis units (1000 dialysis stations) and 100 renal transplant centres catering to an estimated 100 000 new cases of ESRD annually [21] . The annual cost of haemodialysis and continuous ambulatory peritoneal dialysis (CAPD) is 8500 and 9900 USD, respectively, which is 10 times the per capita gross national product of India. In the absence of state-funded medical support or medical insurance facilities, only 3-5% of ESRD patients get some form of RRT. In developed countries, over 80% of the cost of RRT is borne by the state. In India, such a subsidy would amount to 25% of the total health-care budget catering to just 0.01% of the population [8] . While screening for CKD in high-risk patients is established practice in developed countries, it is known from several epidemiologic studies that, for every patient with known HTN or diabetes, there is one individual in the population for whom this diagnosis has not yet been made but who already can have considerable associated end-organ damage [22, 23] . In developing countries, this is even worse, and many individuals with diabetes, HTN or proteinuria may never seek medical care. Preventive measures to postpone ESRD consist of rigid BP control, preferably with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Patients with known diabetes or HTN frequently are already on these regimens. Consequently, the number of individuals identified by targeted screening and for whom such screening results in a change of medical treatment may be limited. While data from the Prevention of Renal and Vascular End-stage Disease Intervention Trial (PRE-VEND IT) study showed that screening for albuminuria and subsequent pharmacological intervention was cost-effective when calculated to prevent cardiovascular end points [24] , Palmer et al. calculated that the earlier the individual at risk is detected and preventive treatment is started, the more cost-effective such treatment will be [25] . A study in the UK estimated that cost of screening for CKD could be recouped by delaying dialysis requirement by just 1 year for one individual per 10 000 patients treated [26] . In our study, previously undiagnosed DM and HTN were found in 1.53% and 13.15%, respectively. Structural kidney damage in the form of MAU, haematuria or leucocyturia in subjects with GFR >60 mL/min/1.73 m 2 was found in 10.01% (CKD-EPI) to 12.02% (MDRD) and hence could be classified as stage I and II CKD. It is in this subset of patients in whom early institution of risk modification behaviour, lifestyle changes and therapeutic intervention may delay or interrupt progression to higher stages of CKD.
Examination of various risk factors for CKD and MAU showed positive correlations for age >40 years, BMI >25, FPG >126 mg/dL and HTN. Singh et al. have observed a positive association between BMI [12] and renal impairment. Sanches et al. have shown a correlation between waist circumference (WC) and between WHR and reduced GFR [27] . These studies have evaluated patients with later stages of CKD and GFR <60 mL/min/1.73 m 2 . Our study has shown that the correlation of these factors can be seen even in early stages of CKD and in apparently healthy individuals. The correlation of risk factors may become stronger as the disease process progresses.
Our study has shown 28.81% overweight, 21.63% obese and 48.53% with abnormal WHR. These figures are much higher than western data and are due to application of much more stringent criteria of the Association of Physicians of India consensus statement for obesity for Asian Indian population [13] . Based on percentage body fat and morbidity data, it was found that limits of normal BMI are narrower and lower in Asian Indians than in white Caucasians, and the use of these new guidelines results in an additional 10-15% of Indian population being labelled as obese or overweight.
There are a few limitations to our study. Our sample comprised salaried class in central government service, and therefore, all socioeconomic classes, especially lower socioeconomic population, and the affluent are not adequately represented. The retirement age in central government service is 60 years, and hence, the sample has only a few dependents (n = 11) of age over 60 years who are at higher risk of CKD. We have also done only spot sampling of MAU, although, ideally, two out of three samples should be positive to label an individual as MAU positive. The logistics of a camp approach that we had followed made a repeat sampling extremely difficult. However, spot sampling has been routinely used as a screening tool in many studies including the initial NHANES cohort and the Singapore Prospective Study Programme [16] .
Conclusion
This study shows 13.12-15.04% of Indian CGEs who have early stages of CKD, and previous figures were gross underestimates of the true prevalence of CKD. The use of markers of structural kidney damage has identified 10.01-12.02% of subjects with stages I and II of CKD. Screening of a general population rather than just targeted populations for CKD is likely to identify more subjects in whom early diagnosis and prevention due to such screening programmes will be beneficial and cost-effective.
Introduction
The most prominent cause of mortality among chronic kidney disease (CKD)-affected patients is cardiovascular events [1] and, therefore, cardiovascular disease (CVD) prevention is of paramount relevance. However, most of the existing data on cardiovascular risk scores (Framingham score) come from the general population and might not be equally applied to CKD patients [2] . In a study of 936 patients on haemodialysis, neither serum total cholesterol nor systolic blood pressure was associated with coronary heart disease, cerebrovascular disease or peripheral vascular disease, and the authors concluded that using the Framingham score in haemodialysis patients is inadequate in predicting coronary heart disease [3] . Furthermore, variables involved in the pathogenesis of atherosclerosis of
